Patents-Review.com
🔗 Permalink
Assignee profile:

IMMUNE DESIGN CORP.

City:

Seattle, Washington

Country:

United States

Published Applications:

22

Last publication date:

2022-03-24

Patent Grants:

16

Last grant date:

2021-10-05

Top Inventors for applications by IMMUNE DESIGN CORP.

These are the the leading inventors for applications assigned to IMMUNE DESIGN CORP.:

Recent patent applications by IMMUNE DESIGN CORP.

IMMUNE DESIGN CORP. based in Seattle, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-03-24
US20220088177A1
Human necessities

RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS

 #2 | 2022-02-24
US20220054627A1
Human necessities

RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS

 #3 | 2020-08-13 ✅ Patent 11,135,283 granted on 2021-10-05
US20200254087A1
Human necessities

Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids

 #4 | 2019-12-12 ✅ Patent 11,365,230 granted on 2022-06-21
US20190375811A1
Chemistry; metallurgy

Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

 #5 | 2019-09-05 ✅ Patent 10,993,956 granted on 2021-05-04
US20190269714A1
Human necessities

GLA monotherapy for use in cancer treatment

 #6 | 2019-05-02 ✅ Patent 10,584,356 granted on 2020-03-10
US20190127759A1
Chemistry; metallurgy

Multigenome retroviral vector preparations and methods and systems for producing and using same

 #7 | 2018-03-01 ✅ Patent 10,391,157 granted on 2019-08-27
US20180055921A1
Human necessities

Materials and methods for producing improved lentiviral vector particles

 #8 | 2017-09-28 ✅ Patent 10,391,164 granted on 2019-08-27
US20170274066A1
Human necessities

Vaccines for HSV-2

 #9 | 2017-09-21 ✅ Patent 10,179,919 granted on 2019-01-15
US20170268020A1
Chemistry; metallurgy

Multigenome retroviral vector preparations and methods and systems for producing and using same

 #10 | 2015-12-17 ✅ Patent 10,342,815 granted on 2019-07-09
US20150359811A1
Human necessities

GLA monotherapy for use in cancer treatment

 #11 | 2015-02-19 ✅ Patent 9,713,635 granted on 2017-07-25
US20150050307A1
Human necessities

Materials and methods for producing improved lentiviral vector particles

 #12 | 2014-11-06 ✅ Patent 8,962,593 granted on 2015-02-24
US20140328904A1
Human necessities

GLA monotherapy for use in cancer treatment

 #13 | 2014-10-23 ✅ Patent 8,957,047 granted on 2015-02-17
US20140314834A1
Chemistry; metallurgy

GLA monotherapy for use in cancer treatment

 #14 | 2014-05-08 ✅ Patent 9,895,435 granted on 2018-02-20
US20140127247A1
Human necessities

Vaccines for HSV-2

 #15 | 2014-03-27 ✅ Patent 9,555,099 granted on 2017-01-31
US20140086947A1
Chemistry; metallurgy

Vaccines for HSV-2

 #16 | 2012-12-27 ✅ Patent 9,044,420 granted on 2015-06-02
US20120328655A1
Human necessities

Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses

 #17 | 2012-12-04 ✅ Patent 8,323,662 granted on 2012-12-04
US13436472
-

Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein

 #18 | 2012-11-15
US20120288515A1
Human necessities

SYNTHETIC LONG PEPTIDE (SLP)-BASED VACCINES

 #19 | 2012-10-18
US20120263754A1
Human necessities

Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines

 #20 | 2012-02-16 ✅ Patent 8,187,872 granted on 2012-05-29
US20120039932A1
Chemistry; metallurgy

Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

 #21 | 2011-12-15
US20110305748A1
Human necessities

Vaccines for Pandemic Influenza

 #22 | 2011-03-17
US20110064763A1
Chemistry; metallurgy

LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN

Also check out IMMUNE DESIGN CORP.'s (Seattle, United States) applicant profile with 14 patent applications submitted.

AssigneeID:

59617 ⎘